Titan Pharmaceuticals IncNASDAQ:TTNP
- LAST PRICE7.3195
- TODAY'S CHANGE (%)0.2195 (3.0915%)
- Bid / Lots6.3600/ 3
- Ask / Lots7.4800/ 15
- Open / Previous Close7.3195 / 7.1000
- Day Range
- 52 Week Range
- Volume2,958
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | TTNP |
|---|---|---|
| 09:54 ET | 400 | 7.3195 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Titan Pharmaceuticals Inc | 6.5M | -1.0x | --- |
Sonnet Biotherapeutics Holdings Inc | 5.4M | -0.1x | --- |
Shuttle Pharmaceuticals Holdings Inc | 6.7M | -0.9x | --- |
Eastgate Biotech Corp | 5.7M | -1.6x | --- |
Vestiage Inc | 5.9M | 12.0x | --- |
GT Biopharma Inc | 5.2M | -0.7x | --- |
Company Information
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
Contact Information
- Headquarters
- SUITE 505, 400 OYSTER POINT BLVDSAN FRANCISCO, CA, United States 94080
- Phone
- 415-244-4990
- Fax
- 650-244-4956
Executives
- Chairman of the Board, Chief Executive Officer, Principal Financial Officer
- Gim Shen Seow
- Director
- Brynner Chiam
- Independent Director
- Avraham Ben-Tzvi
- Independent Director
- Firdauz Edmin Bin Mokhtar
- Independent Director
- Francisco Garcia
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.5M |
|---|---|
Revenue (TTM) | $185.0K |
Shares Outstanding | 914.2K |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.31 |
EPS | $-7.40 |
Book Value | $8.50 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | 35.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -3,933.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
